{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:21:18Z","timestamp":1699971678264},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.jhep.2005.02.037","type":"journal-article","created":{"date-parts":[[2005,5,15]],"date-time":"2005-05-15T05:27:36Z","timestamp":1116134856000},"page":"217-224","source":"Crossref","is-referenced-by-count":17,"title":["Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir\u2013lamivudine combination therapy"],"prefix":"10.1016","volume":"43","author":[{"given":"Ulrike","family":"Mihm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara Christine","family":"G\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Faust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf Peter","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2005.02.037_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.02.037_bib2","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.02.037_bib3","first-page":"44 (A)","article-title":"Incremental increases in HBeAg-seroconversion and continued ALT normalisation in Asian chronic HBV patients treated with lamivudine for four years","volume":"5","author":"Chang","year":"2000","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2005.02.037_bib4","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.02.037_bib5","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.510300427","article-title":"Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy","volume":"30","author":"Dienstag","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.02.037_bib7","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","article-title":"Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy","volume":"33","author":"Leung","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","article-title":"Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia hepatitis lamivudine study group","volume":"119","author":"Liaw","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.02.037_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/hep.510290321","article-title":"Efficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group","volume":"29","author":"Tassopoulos","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/jhep.2000.17915","article-title":"Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"32","author":"Hadziyannis","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(01)05840-8","article-title":"Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study","volume":"358","author":"Benhamou","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.02.037_bib12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.02.037_bib13","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.02.037_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/jhep.2000.8626","article-title":"Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants","volume":"32","author":"Perrillo","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2003.10.050","article-title":"Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus","volume":"126","author":"Perrillo","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.02.037_bib16","first-page":"1419","article-title":"Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients","volume":"38","author":"Schiff","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/jhep.2003.50288","article-title":"Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B","volume":"38","author":"Westland","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2002.34740","article-title":"Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks","volume":"36","author":"Yang","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","article-title":"Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B","volume":"126","author":"Peters","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.02.037_bib20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0016-5085(03)00939-9","article-title":"Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase","volume":"125","author":"Angus","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.02.037_bib21","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2003.09.022","article-title":"Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient","volume":"39","author":"Villeneuve","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.02.037_bib22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1128\/AAC.44.3.551-560.2000","article-title":"In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir","volume":"44","author":"Colledge","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2005.02.037_bib23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1053\/jhep.2000.9143","article-title":"Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study","volume":"32","author":"Lau","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib24","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/jhep.2001.28509","article-title":"Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed","volume":"34","author":"Lewin","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib25","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","article-title":"Viral dynamics in hepatitis B virus infection","volume":"93","author":"Nowak","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2005.02.037_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1600-0676.2002.01579.x","article-title":"Viral dynamics in chronic hepatitis B patients during lamivudine therapy","volume":"22","author":"Wolters","year":"2002","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2005.02.037_bib27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/00042737-200209000-00012","article-title":"Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir","volume":"14","author":"Wolters","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2005.02.037_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0168-8278(02)00113-7","article-title":"The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine","volume":"37","author":"Wolters","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.02.037_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0168-8278(97)80345-5","article-title":"Dynamics of hepatitis B virus infection in vivo","volume":"27","author":"Zeuzem","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.02.037_bib30","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.510290626","article-title":"Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy","volume":"29","author":"Tsiang","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib31","first-page":"54","article-title":"Effect of varying dose on the dynamics of hepatitis B virus clearance from the serum of patients treated with adefovir dipivoxil","volume":"30","author":"Tsiang","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.02.037_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jhep.2005.02.037_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0168-8278(02)00115-0","article-title":"Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B","volume":"37","author":"Wolters","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.02.037_bib34","first-page":"1410","article-title":"Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes","volume":"38","author":"Kock","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib35","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/jhep.2003.50218","article-title":"Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon","volume":"37","author":"Herrmann","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib36","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1128\/JCM.37.9.2793-2797.1999","article-title":"Automated quantitative analysis of hepatitis B virus DNA by using the Cobas Amplicor HBV monitor test","volume":"37","author":"Noborg","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2005.02.037_bib37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1053\/jhep.2003.50344","article-title":"Dynamics of alanine aminotransferase during hepatitis C virus treatment","volume":"38","author":"Ribeiro","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib38","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.510300313","article-title":"Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group","volume":"30","author":"Chien","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib39","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/jhep.2002.34294","article-title":"Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B","volume":"36","author":"Perrillo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0016-5085(03)00700-5","article-title":"Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1","volume":"125","author":"Westland","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.02.037_bib41","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1172\/JCI3731","article-title":"Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B","volume":"102","author":"Boni","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2005.02.037_bib42","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/jhep.2001.23045","article-title":"Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy","volume":"33","author":"Boni","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.02.037_bib43","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","article-title":"Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B","volume":"39","author":"Boni","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.02.037_bib44","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.174.6.1565","article-title":"Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen","volume":"174","author":"Penna","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2005.02.037_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0166-3542(91)90059-Z","article-title":"Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models","volume":"16","author":"Del","year":"1991","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2005.02.037_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0168-8278(02)80016-2","article-title":"Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: a multicentre, controlled study","volume":"36","author":"Cooksley","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.02.037_bib47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0168-8278(91)90074-L","article-title":"Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B","volume":"13","author":"Jung","year":"1991","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.02.037_bib48","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.181.3.1047","article-title":"The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis","volume":"181","author":"Rehermann","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2005.02.037_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jhep.2005.02.037_bib50","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1128\/JVI.74.3.1495-1505.2000","article-title":"Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections","volume":"74","author":"Guo","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2005.02.037_bib51","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1084\/jem.191.8.1269","article-title":"The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection","volume":"191","author":"Maini","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2005.02.037_bib52","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2893.2004.00523.x","article-title":"Kinetics of hepatitis B viral load during 48 weeks of treatment with 600mg versus 100mg of lamivudine daily","volume":"11","author":"Wang","year":"2004","journal-title":"J Viral Hepat"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827805002746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827805002746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T10:06:28Z","timestamp":1586253988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827805002746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0168827805002746"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2005.02.037","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}